Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

被引：0

作者：

Greenberg, Arthur ^{[1
]}

机构：

[1] Duke Univ, Dept Med, Div Nephrol, Med Ctr, Durham, NC 27710 USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 50卷 / 06期

关键词：

D O I：

10.1053/j.ajkd.2007.10.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：904 / 907

页数：4

共 13 条

[11] PATHOGENESIS OF SODIUM AND WATER-RETENTION IN HIGH-OUTPUT AND LOW-OUTPUT CARDIAC-FAILURE, NEPHROTIC SYNDROME, CIRRHOSIS, AND PREGNANCY .1. [J].

SCHRIER, RW .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (16) :1065-1072

[12] Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction [J].

Udelson, James E. ;

McGrew, Frank A. ;

Flores, Enrique ;

Ibrahim, Hassan ;

Katz, Stewart ;

Koshkarian, Gregory ;

O'Brien, Terrence ;

Kronenberg, Marvin W. ;

Zimmer, Christopher ;

Orlandi, Cesare ;

Konstam, Marvin A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (22) :2151-2159

[13] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure [J].

Udelson, JE ;

Smith, WB ;

Hendrix, GH ;

Painchaud, CA ;

Ghazzi, M ;

Thomas, I ;

Ghali, JK ;

Selaru, P ;

Chanoine, F ;

Pressler, ML ;

Konstam, MA .

CIRCULATION, 2001, 104 (20) :2417-2423

← 1 2 →